drugset / Trial / NCT05290792

Use of Wearable Sensors for Early Detection and Tracking of Viral Respiratory Tract Infections

NCT05290792

NaSingle-groupOpen-labelScreening

Summary

Viral respiratory tract infections (VRTI) are among the most common human illnesses, impacting billions globally. There is an unmet need to identify novel ways to detect, treat and prevent their spread. New wearable devices could address this need, using special biosensors worn by patients. This is a single centre, controlled, before and after, longitudinal, clinical trial. Participants will receive FluMist, a live attenuated influenza vaccine, which will act as a proxy to a viral respiratory tract infection and create a very minor response to the immune system. Vital signs and activity levels will be monitored continuously using wearable biosensors for 7 days prior to and 7 days following, along with symptom tracking and blood tests to measure immune responses. Artificial intelligence (AI) and machine learning (ML) algorithms will be used to analyse the data. AI and ML will identify subtle changes in vital signs and activity levels from the immune response to respiratory viruses. These data will help develop future methods to address important public health questions related to respiratory virus detection, containment and management. The purpose of this study is to explore whether wearable sensors can detect, track the progress and recovery from viral respiratory tract infection.

Timeline

Start
2021-12-10
Primary completion
2022-10-31
Completion
2022-10-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine Intranasal

Indications